LINC01605 promotes aerobic glycolysis through lactate dehydrogenase A in triple‐negative breast cancer

Abstract

Breast cancer is the most prevalent cancer diagnosed in women and the major malignancy that threatens women health, thus we explored the role of long noncoding RNA LINC01605 in triple‐negative breast cancer (TNBC). We collected tissue samples from TNBC patients and cultured breast cancer cells to detect LINC01605 levels by RT‐PCR. We then constructed LINC01605 knockdown and LINC01605 overexpressed TNBC cell lines, cell proliferation was measured by CCK‐8 and colony formation assays, cell migration and invasion were measured by Transwell assay, and aerobic glycolysis of cells was detected. Furthermore, a downstream target gene was found, and its role was confirmed by mouse allogeneic tumor formation. It discovered that LINC01605 expression was significantly increased in TNBC patients, and its high expression predicted a low survival prognosis for TNBC patients. Stable knockdown of LINC01605 remarkably inhibited cell proliferation, migration, and invasion, as well as aerobic glycolysis by inhibiting lactate dehydrogenase A in TNBC cell lines. Notably, knockdown of LINC01605 suppressed in vivo tumor formation and migration in TNBC transplanted mice. In conclusion, targeting long noncoding RNA LINC01605 might serve as a therapeutic candidate strategy to treat patients with TNBC.

The lncRNA LINC01605 promotes the progression of pancreatic ductal adenocarcinoma by activating the mTOR signaling pathway

“…As described above, LINC01605 was ltered out prudently. As a promising lncRNA, LINC01605 has been studied in breast cancer [10],…”

“…To date, LINC01605 has been reported to participate in miR-3960/SOX11 [8] and METTL3/SPTBN2 regulation [12] and to play a role in the EMT signaling pathway with MMP9 [9] and the NF-κB pathway [13] or metabolic processes such as aerobic glycolysis [10]. However, whether LINC01605 regulates tumor cells via the mTOR signaling pathway remains unclear.…”

A cuproptosis-related lncRNA signature identified prognosis and tumour immune microenvironment in kidney renal clear cell carcinoma

“…After identifying the prognostic lncRNAs differentially expressed in normal and KIRC tissues, we comprehensively employed the univariate and LASSO COX regression analysis to determine four lncRNAs (LINC01605, AGAP2-AS1, FOXD2-AS1, and LINC02195) and construct the prognostic signature (CRGscore) associated with the OS. LINC01605 has been demonstrated in triple negative breast cancer, nasopharyngeal carcinoma, colorectal cancer, and other cancers to promote tumor proliferation and invasion through multiple pathways ( Hu et al, 2021b ; Wang et al, 2022a ; Zhao et al, 2022 ). AGAP2-AS1 was confirmed to be a prognostic marker of KIRC through the TCGA-KIRC cohort and a self-collected independent cohort ( Gao et al, 2020 ; Nakken et al, 2021 ).…”

Non-coding RNAs in breast cancer: with a focus on glucose metabolism reprogramming

“…In recent years, LncRNALINC01605 has been found to be upregulated in a variety of cancers and to accelerate tumor proliferation. Wang et al found that LINC01605 promoted proliferation and invasion of TNBC cells in vitro and directly targeted the upregulation of LDHA expression [ 45 ]. In addition, Chu et al used relevant breast cancer data to search for lncRNAs that negatively regulate PGK1, and experimentally confirmed that LncRNALINC00926 downregulates breast cancer cell proliferation and metastasis by enhancing E3 ligase STUB1-mediated ubiquitination of PGK1 and downregulating the level of glycolytic reprogramming in cancer cells.…”